Søborg, Denmark

Søren Bregenholt Frederiksen

USPTO Granted Patents = 1 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2012

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Søren Bregenholt Frederiksen

Introduction

Søren Bregenholt Frederiksen is a notable inventor based in Søborg, Denmark. He has made significant contributions to the field of biotechnology, particularly in the development of recombinant polyclonal antibodies. His work is aimed at improving therapeutic and prophylactic treatments.

Latest Patents

Frederiksen holds a patent for an "Anti-Rhesus D recombinant polyclonal antibody." This invention relates to a method for manufacturing an anti-RhD recombinant polyclonal antibody composition (anti-RhD rpAb). The method involves obtaining a collection of cells transfected with a library of anti-RhD antibody expression vectors. Each cell in this collection is capable of expressing a distinct member of the anti-RhD recombinant polyclonal antibody composition. The cells are cultured under suitable conditions for the expression of the recombinant polyclonal antibody, which is then obtained from the cells or culture supernatant. This innovative method provides a superior replacement for plasma-derived prophylactic and therapeutic immunoglobulin products.

Career Highlights

Frederiksen is currently associated with Symphogen A/S, where he continues to advance his research and development efforts. His work has been instrumental in the field of immunology, particularly in creating effective antibody therapies.

Collaborations

Some of his notable coworkers include Søren Kofoed Rasmussen and Anne Bondgaard Tolstrup. Their collaborative efforts contribute to the innovative environment at Symphogen A/S.

Conclusion

Søren Bregenholt Frederiksen's contributions to biotechnology, particularly through his patent on anti-RhD recombinant polyclonal antibodies, highlight his role as a significant inventor in the field. His work continues to pave the way for advancements in therapeutic treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…